This is a randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare 2 dose levels of BDA MDI (PT027) to its components BD MDI (PT008) and AS MDI (PT007) on improvement in lung function and asthma symptoms after 12 weeks of treatment in adult, adolescent, and child subjects with symptomatic asthma currently being treated with a short/rapid-acting 2-adrenoreceptor agonist (SABA; eg, Ventolin) as needed alone or with low-dose inhaled corticosteroid (ICS) maintenance therapy plus SABA as needed.
| Condition | Asthma, Asthma, Asthma (Pediatric), Allergies & Asthma, Allergies & Asthma, Asthma (Pediatric), asthmatic, bronchial asthma |
|---|---|
| Treatment | Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg, Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Albuterol sulfate metered-dose inhaler 180 μg, Budesonide metered-dose inhaler 160 µg, Placebo metered-dose inhaler |
| Clinical Study Identifier | NCT03847896 |
| Sponsor | Bond Avillion 2 Development LP |
| Last Modified on | 28 May 2022 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.